Dr. Kramer examines how certain antidepressants can alter personality traits, while also exploring the ethical concerns and long-term effects of these changes.
NbN helps to address stigma by emphasizing the pharmacological properties of medications rather than terms that may lead to misunderstandings among patients and their families
Finding the right stimulant dose for adult ADHD can be tough. This study looked at how higher doses beyond FDA limits affect symptom control and side effects.
Listen to the full text of the issue read aloud by Gregory Malzberg, MD. Gepirone (Exxua) gets a critical review. The Neuroscience-Based Nomenclature reclassifies psych meds, and Peter Kramer reflects on whether SSRIs change personality 30 years after his classic Listening to Prozac.
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
